Vaccines - Iran

  • Iran
  • The Vaccines market in Iran is expected to reach a projected revenue of US$387.90m in 2024.
  • This revenue is forecasted to experience an annual growth rate (CAGR 2024-2029) of 8.79%, leading to a market volume of US$591.10m by 2029.
  • When compared globally, United States is projected to generate the highest revenue of US$29,120.00m in 2024.
  • Iran's domestic production of vaccines has been steadily increasing, reducing its reliance on imported vaccines.

Key regions: Australia, Italy, France, South Korea, Brazil

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

Iran, a country in the Middle East, has been making strides in the healthcare industry in recent years. The vaccines market in Iran has been developing in a positive direction, with a growing demand for preventive care and an increase in government investment in healthcare.

Customer preferences:
The Iranian population has been showing an increased interest in preventive care, leading to a rise in demand for vaccines. This trend is in line with the global shift towards preventative healthcare. Additionally, the Iranian government has been implementing vaccination programs, particularly for children, which has further increased the demand for vaccines.

Trends in the market:
The vaccines market in Iran has been growing steadily in recent years. The market is mainly dominated by local manufacturers, with a few international players also present. The most commonly used vaccines in Iran include those for polio, tetanus, and measles. There has been a growing interest in newer vaccines, such as those for HPV and meningitis, which are becoming more widely available in the country.

Local special circumstances:
Iran has a large and growing population, with a significant proportion being under the age of 30. This demographic shift has led to an increased demand for healthcare services, including vaccines. Additionally, the country has been facing a number of health challenges, including outbreaks of diseases such as measles and polio. The government has been working to address these challenges by investing in healthcare infrastructure and implementing vaccination programs.

Underlying macroeconomic factors:
The Iranian economy has been facing a number of challenges in recent years, including sanctions and a decline in oil prices. However, the government has continued to prioritize healthcare spending, which has helped to support the growth of the vaccines market. Additionally, the country has a strong pharmaceutical industry, which has helped to support the development and production of vaccines locally. Overall, the vaccines market in Iran has been developing in a positive direction, with a growing demand for preventive care and an increase in government investment in healthcare. While there are still challenges to be addressed, such as outbreaks of diseases and economic instability, the outlook for the vaccines market in Iran remains positive.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)